Concepedia

Publication | Open Access

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

DOIFull Paper Access

18

Citations

23

References

2018

Year

María Fernanda Guerra Veloz, Juan María Vázquez Morón, María Belvis Jiménez, Héctor Pallarés Manrique, Teresa Valdés Delgado, Luisa Castro Laria, Belén Maldonado Pérez, A. Benítez Roldán, Raúl Perea Amarillo, Vicente López Merino,
Revista Española de Enfermedades Digestivas

Abstract

switching from infliximab RP to CT-P13 is safe and effective at 12 months. The loss of efficacy at 12 months was 15.7%.

References

YearCitations

Page 1